Companies
Buyer's remorse at AbbVie
AbbVie is considering abandoning its deal with Shire because of a US clampdown on so-called tax inversions. Lex's Robert Armstrong and Oliver Ralph discuss the logic of the pharma tie-up and why the sums may no longer add up.